Literature DB >> 8995642

Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site.

S Ethelberg1, B Hallberg, J Lovmand, J Schmidt, A Luz, T Grundström, F S Pedersen.   

Abstract

SL3-3 is a highly T-lymphomagenic murine retrovirus. Previously, mutation of binding sites in the U3 repeat region for the AML1 transcription factor family (also known as core binding factor [CBF], polyomavirus enhancer binding protein 2 [PEBP2], and SL3-3 enhancer factor 1 [SEF1]) were found to strongly reduce the pathogenicity of SL3-3 (B. Hallberg, J. Schmidt, A. Luz, F. S. Pedersen, and T. Grundström, J. Virol. 65:4177-4181, 1991). We have now examined the few cases in which tumors developed harboring proviruses that besides the AML1 (core) site mutations carried second-site alterations in their U3 repeat structures. In three distinct cases we observed the same type of alteration which involved deletions of regions known to contain binding sites for nuclear factor 1 (NF1) and the addition of extra enhancer repeat elements. In transient-expression experiments in T-lymphoid cells, these new U3 regions acted as stronger enhancers than the U3 regions of the original viruses. This suggests that the altered proviruses represent more-pathogenic variants selected for in the process of tumor formation. To analyze the proviral alterations, we generated a series of different enhancer-promoter reporter constructs. These constructs showed that the additional repeat elements are not critical for enhancer strength, whereas the NF1 sites down-regulate the level of transcription in T-lymphoid cells whether or not the AML1 (core) sites are functional. We therefore also tested SL3-3 viruses with mutated NF1 sites. These viruses have unimpaired pathogenic properties and thereby distinguish SL3-3 from Moloney murine leukemia virus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995642      PMCID: PMC191173     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

Review 1.  Virus-host interactions and the pathogenesis of murine and human oncogenic retroviruses.

Authors:  P N Tsichlis; P A Lazo
Journal:  Curr Top Microbiol Immunol       Date:  1991       Impact factor: 4.291

2.  PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene.

Authors:  E Ogawa; M Maruyama; H Kagoshima; M Inuzuka; J Lu; M Satake; K Shigesada; Y Ito
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

3.  Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia.

Authors:  P Liu; S A Tarlé; A Hajra; D F Claxton; P Marlton; M Freedman; M J Siciliano; F S Collins
Journal:  Science       Date:  1993-08-20       Impact factor: 47.728

4.  Murine helix-loop-helix transcriptional activator proteins binding to the E-box motif of the Akv murine leukemia virus enhancer identified by cDNA cloning.

Authors:  A L Nielsen; N Pallisgaard; F S Pedersen; P Jørgensen
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

5.  A proline-rich TGF-beta-responsive transcriptional activator interacts with histone H3.

Authors:  A Alevizopoulos; Y Dusserre; M Tsai-Pflugfelder; T von der Weid; W Wahli; N Mermod
Journal:  Genes Dev       Date:  1995-12-15       Impact factor: 11.361

6.  Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins.

Authors:  W Sun; B J Graves; N A Speck
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

8.  Regulation of the DNA-binding and transcriptional activities of Xenopus laevis NFI-X by a novel C-terminal domain.

Authors:  E Roulet; M T Armentero; G Krey; B Corthésy; C Dreyer; N Mermod; W Wahli
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

9.  Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian Runt domain.

Authors:  S C Bae; E Takahashi; Y W Zhang; E Ogawa; K Shigesada; Y Namba; M Satake; Y Ito
Journal:  Gene       Date:  1995-07-04       Impact factor: 3.688

10.  The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript.

Authors:  H Miyoshi; T Kozu; K Shimizu; K Enomoto; N Maseki; Y Kaneko; N Kamada; M Ohki
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

View more
  19 in total

1.  Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.

Authors:  M J Martiney; K Rulli; R Beaty; L S Levy; J Lenz
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.

Authors:  S Ethelberg; B D Tzschaschel; A Luz; S J Diaz-Cano; F S Pedersen; J Schmidt
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.

Authors:  S Ethelberg; J Lovmand; J Schmidt; A Luz; F S Pedersen
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element.

Authors:  Ditte Ejegod; Karina Dalsgaard Sørensen; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

5.  CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes.

Authors:  A L Zaiman; A Nieves; J Lenz
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  Analysis of wild-type and mutant SL3-3 murine leukemia virus insertions in the c-myc promoter during lymphomagenesis reveals target site hot spots, virus-dependent patterns, and frequent error-prone gap repair.

Authors:  Anne Ahlmann Nielsen; Annette Balle Sørensen; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants.

Authors:  H W Amtoft; A B Sørensen; C Bareil; J Schmidt; A Luz; F S Pedersen
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

8.  An SL3-3 murine leukemia virus enhancer variant more pathogenic than the wild type obtained by assisted molecular evolution in vivo.

Authors:  S Ethelberg; A B Sørensen; J Schmidt; A Luz; F S Pedersen
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

9.  B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer.

Authors:  J Lovmand; A B Sorensen; J Schmidt; M Ostergaard; A Luz; F S Pedersen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus.

Authors:  M J Martiney; L S Levy; J Lenz
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.